ABVC BioPharma Inc
ABVC
Get informed when a big investor buys or sells
+ FollowMarket Cap$22.17M
Close$
$-0.12
106.7% downside
Current Fair Value
106.7% downsideOvervalued by 106.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $22.17 Million |
|---|---|
| Enterprise Value | $24.77 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.39 |
| Beta | 0.57 |
| Outstanding Shares | 25,448,516 |
Return
| Return on Equity | -6.01% |
|---|---|
| Return on Assets | -3.28% |
| Return on Invested Capital | -46.38% |
Valuation & Multiples
| P/E Ratio | -13.32 |
|---|---|
| PEG | -15.61 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 15.56 |
| Enterprise Value to EBIT | -3.73 |
| Enterprise Value to Net Income | -39 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
$-0.40
Average shareholder expectationRevenue Estimate
$113,257
Average shareholder expectationNext Earnings Call
Expected Date
August 18, 2026
EPS Estimate
$-0.40
Average shareholder expectationRevenue Estimate
$113,257
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About ABVC BioPharma Inc
34 employees